Cells within a tumor sample are known to be heterogeneous, due to the contamination from non-malignant tissue or the presence of multiple sub-clones, each carrying different somatic mutations. The majority of somatic mutations identified to date are clustered (mutational hotspots) in the functional sites of a few "cancer genes" with key roles in cell signaling pathways of proliferation and survival. Somatic mutations in cancer genes modify their oncogenic potential or affect sensitivity to therapy. Currently available assays that are able to detect rare somatic mutations are not comprehensive. They are usually focused on a few commonly mutated loci, and not implemented in clinical setting due to cost or technical reasons. Therefore, a current technological need exists for an assay that can reliably detect and accurately measure the prevalence of multiple somatic mutations present only in a fraction of the cells in a heterogeneous tumor. Such an assay would facilitate translational research to study the selection of tumor sub-clones during disease progression and treatment. Additionally the assay could be used by clinicians to improve tumor characterization and selection of therapy choices during clinical trials. We propose to leverage the emerging technology of targeted high-throughput sequencing to develop a cost- effective assay capable of detecting somatic mutations that are present in e1% of tumor cells. Specifically we will perform ultra-deep targeted sequencing (UDT-Seq) of ~100 kb in each tumor assaying 518 mutational hotspots located in 46 cancer genes. The selected mutational hotspots cover ~87% of all entries in the COSMIC database. We will develop a streamlined sample preparation in collaboration with RainDance Technologies to ensure a straightforward implementation in the clinic. This sample preparation integrates the targeting PCR and the library preparation in one step using chimeric PCR primers. The amplified targeted hotspots (200bp long) will be thus directly sequenced on the Illumina Genome Analyzer (GAII) at a very high coverage (~20,000x). We will then precisely model the sequencing error using calibration samples to filter true mutations from the sequencing noise.
Our specific aims are: 1) To calibrate the UDT-Seq assay by analyzing both pooled DNA samples containing precise ratios of known SNPs and DNA samples spiked with low amounts of mutated DNA from cancer cells. For this, we will develop a statistical sequencing error model to detect rare mutations in deep sequence. 2) To evaluate the accuracy of the UDT- Seq assay to detect rare somatic mutations in both frozen and formalin fixed paraffin embedded solid tumors. If the quantitative milestones set for this pilot phase of the UDT-Seq assay development are met, we will apply for R33 funding to further develop and make this assay broadly available to clinical oncologists for their own translational research through a CLIA laboratory.

Public Health Relevance

We propose to develop an assay to analyze somatic mutations in rare subclones of solid-tumors. This assay will feature microfluidic-based sample preparation method and high throughput DNA sequencing. It would be the most comprehensive assay to identify rare somatic mutational hotspots in a clinical setting and clinical oncologists will potentially use this assay to identify new biomarkers for disease progression or predictive of drug response, for a more personalized treatment of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21CA155615-02
Application #
8337324
Study Section
Special Emphasis Panel (ZCA1-SRLB-V (M1))
Program Officer
Sorg, Brian S
Project Start
2011-09-22
Project End
2013-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
2
Fiscal Year
2012
Total Cost
$154,699
Indirect Cost
$54,893
Name
University of California San Diego
Department
Pediatrics
Type
Schools of Medicine
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Murphy, Derek M; Castellanos-Rizaldos, Elena; Makrigiorgos, G Mike (2014) Enriching mutant sequences by modulating the denaturation time during PCR. Clin Chem 60:1014-6
Castellanos-Rizaldos, Elena; Milbury, Coren A; Karatza, Elli et al. (2014) COLD-PCR amplification of bisulfite-converted DNA allows the enrichment and sequencing of rare un-methylated genomic regions. PLoS One 9:e94103
Barrett, Christian L; Schwab, Richard B; Jung, HyunChul et al. (2013) Transcriptome sequencing of tumor subpopulations reveals a spectrum of therapeutic options for squamous cell lung cancer. PLoS One 8:e58714
Guha, Minakshi; Castellanos-Rizaldos, Elena; Liu, Pingfang et al. (2013) Differential strand separation at critical temperature: a minimally disruptive enrichment method for low-abundance unknown DNA mutations. Nucleic Acids Res 41:e50
Yost, Shawn E; Alakus, Hakan; Matsui, Hiroko et al. (2013) Mutascope: sensitive detection of somatic mutations from deep amplicon sequencing. Bioinformatics 29:1908-9
Yost, Shawn E; Pastorino, Sandra; Rozenzhak, Sophie et al. (2013) High-resolution mutational profiling suggests the genetic validity of glioblastoma patient-derived pre-clinical models. PLoS One 8:e56185
He, Guobin; Dhar, Debanjan; Nakagawa, Hayato et al. (2013) Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell 155:384-96